期刊
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
卷 91, 期 -, 页码 -出版社
ACAD BRASILEIRA DE CIENCIAS
DOI: 10.1590/0001-3765201920190105
关键词
Brazilian biodiversity; new drug development; drug discovery; cosmetic
The global medicine market is about 1.1 trillion US dollars. About 35 percent of medicines have originated from natural products. Brazil presents the largest biodiversity in the world, with more than 50,000 species of higher plants. However, few innovative products have been developed in Brazil from active constituents derived from the Brazilian biodiversity. Scientific evidences on plants and venoms have been internationally published by Brazilian scientists over the last 4 decades; but few examples of innovative products are commercially available. Few examples include the anti-hypertensive drug captopril first identified in the venom of the Brazilian viper Bothrops jararaca by Professor Sergio Ferreira; and some phytotherapeutic agents such as Acheflan (R), Syntocalmy (R) and Melagriao (R) produced by standardized plant extracts with scientific proof of safety, efficacy and quality. Still, only Acheflan (R) and Melagriao (R) are obtained from native Brazilian plants. Several issues contribute to the lack of innovative products from the Brazilian biodiversity, but in my opinion, the most challenging ones are i) the lack of specific regulations to allow researchers and companies to access biodiversity for the purposes of scientific and technological innovation; and ii) the absence of a long-term government program to support research and innovation in this field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据